F Stephen Hodi

List of Publications by Year
in descending order

185	83,078	4942 84	4535 171
papers	citations	h-index	g-index

188	188	188	60222
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New England Journal of Medicine, 2010, 363, 711-723.	13.9	13,065
2	Safety, Activity, and Immune Correlates of Antiâ€“PD-1 Antibody in Cancer. New England Journal of Medicine, 2012, 366, 2443-2454.	13.9	10,727
3	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New England Journal of Medicine, 2015, 373, 23-34.	13.9	6,773
4	Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature, 2014, 515, 563-567.	13.7	4,342
5	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2017, 377, 1345-1356.	13.9	3,589
6	Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria. Clinical Cancer Research, 2009, 15, 7412-7420.	3.2	2,857
7	Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. New England Journal of Medicine, 2015, 372, 2006-2017.	13.9	2,489
8	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2019, 381, 1535-1546.	13.9	2,484
9	Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. Journal of Clinical Oncology, 2015, 33, 1889-1894.	0.8	1,809
10	iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncology, The, 2017, 18, e143-e152.	5.1	1,612
11	Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell, 2017, 171, 934-949.e16.	13.5	1,515
12	Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nature Immunology, 2019, 20, 326-336.	7.0	1,148
13	RECIST 1.1â€”Update and clarification: From the RECIST committee. European Journal of Cancer, 2016, 62, 132-137.	1.3	1,143
14	Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 1480-1492.	5.1	1,089
15	Overall Survival and Long-Term Safety of Nivolumab (Antiâ€“Programmed Death 1 Antibody, BMS-936558,) Tj ETQq1 1 0.784314 rgB Clinical Oncology, 2015, 33, 2004-2012.	0.8	1,035
16	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. New England Journal of Medicine, 2018, 379, 722-730.	13.9	983
17	Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. Journal of Clinical Oncology, 2017, 35, 785-792.	0.8	930
18	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science, 2018, 359, 801-806.	6.0	898

#	Article	IF	Citations
19	A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell, 2018, 175, 984-997.e24.	13.5	892
20	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA - Journal of the American Medical Association, 2016, 315, 1600.	3.8	857
21	Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncology, The, 2016, 17, 1558-1568.	5.1	827
22	Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nature Reviews Clinical Oncology, 2017, 14, 655-668.	12.5	787
23	Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens. JAMA Oncology, 2018, 4, 173.	3.4	753
24	Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncology, The, 2015, 16, e270-e278.	5.1	711
25	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. Journal of Clinical Oncology, 2016, 34, 1510-1517.	0.8	627
26	Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3005-3010.	3.3	604
27	Incidence of Programmed Cell Death 1 Inhibitorâ€“Related Pneumonitis in Patients With Advanced Cancer. JAMA Oncology, 2016, 2, 1607.	3.4	600
28	Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. Journal of Clinical Oncology, 2013, 31, 3182-3190.	0.8	530
29	Programmed Death-Ligand 1 Expression and Response to the Antiâ€“Programmed Death 1 Antibody Pembrolizumab in Melanoma. Journal of Clinical Oncology, 2016, 34, 4102-4109.	0.8	528
30	Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney International, 2016, 90, 638-647.	2.6	524
31	STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Research, 2016, 76, 999-1008.	0.4	451
32	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. Journal of Clinical Oncology, 2022, 40, 127-137.	0.8	446
33	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nature Genetics, 2018, 50, 1271-1281.	9.4	438
34	Major Response to Imatinib Mesylate in KIT-Mutated Melanoma. Journal of Clinical Oncology, 2008, 26, 2046-2051.	0.8	430
35	MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Science Translational Medicine, 2018, 10, .	5.8	425
36	PD-1 Inhibitorâ€“Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. Clinical Cancer Research, 2016, 22, 6051-6060.	3.2	393

#	Article	IF	Citations
37	Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discovery, 2018, 8, 196-215.	7.7	392
38	Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Nonâ€“Small Cell Lung Cancer Treated With Nivolumab. JAMA Oncology, 2019, 5, 1411.	3.4	388
39	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. Journal of Clinical Oncology, 2015, 33, 2013-2020.	0.8	385
40	A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nature Medicine, 2020, 26, 792-802.	15.2	381
41	Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. Journal of Clinical Oncology, 2017, 35, 3807-3814.	0.8	364
42	Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunology Research, 2017, 5, 312-318.	1.6	354
43	Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. Endocrine Reviews, 2019, 40, 17-65.	8.9	349
44	Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunology Research, 2016, 4, 124-135.	1.6	339
45	Combination immunotherapy: a road map. , 2017, 5, 16.		325
46	Antibody-mediated inhibition of MICA and MICB shedding promotes NK cellâ€“driven tumor immunity. Science, 2018, 359, 1537-1542.	6.0	323
47	Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma. JAMA - Journal of the American Medical Association, 2014, 312, 1744.	3.8	312
48	Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncology, The, 2016, 17, 943-955.	5.1	293
49	Landscape of tumor-infiltrating T cell repertoire of human cancers. Nature Genetics, 2016, 48, 725-732.	9.4	288
50	Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. Journal of Clinical Oncology, 2018, 36, 850-858.	0.8	288
51	Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunology Research, 2017, 5, 480-492.	1.6	284
52	Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. Cell, 2020, 182, 655-671.e22.	13.5	259
53	Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunology Research, 2015, 3, 1158-1164.	1.6	237
54	Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab. Cancer Immunology Research, 2015, 3, 1185-1192.	1.6	227

#	Article	IF	Citations
55	Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade. Cancer Immunology Research, 2014, 2, 643-654.	1.6	226
56	Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study. Clinical Cancer Research, 2015, 21, 749-755.	3.2	223
57	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clinical Cancer Research, 2018, 24, 4960-4967.	3.2	222
58	RECIST 1.1 â€“ Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. European Journal of Cancer, 2016, 62, 138-145.	1.3	211
59	Conserved Interferon-Î³ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell, 2020, 38, 500-515.e3.	7.7	203
60	Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data. Frontiers in Oncology, 2015, 5, 202.	1.3	201
61	A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. OncoImmunology, 2015, 4, e1046028.	2.1	191
62	Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treatment Reviews, 2014, 40, 1056-1064.	3.4	178
63	Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. Cancer, 2017, 123, 3285-3290.	2.0	170
64	CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nature Clinical Practice Oncology, 2008, 5, 557-561.	4.3	164
65	Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. , 2018, 6, 26.		150
66	Imaging of Cancer Immunotherapy: Current Approaches and Future Directions. Radiology, 2019, 290, 9-22.	3.6	147
67	Prevalence of antibodies to 3 retroviruses in a captive colony of macaque monkeys. International Journal of Cancer, 1988, 41, 601-608.	2.3	143
68	Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 98, 344-351.	0.4	143
69	Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nature Communications, 2019, 10, 4346.	5.8	139
70	Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research, 2020, 26, 2565-2572.	3.2	138
71	Antiâ€“PD-1 Inhibitorâ€“Related Pneumonitis in Nonâ€“Small Cell Lung Cancer. Cancer Immunology Research, 2016, 4, 289-293.	1.6	135
72	Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression. JAMA Oncology, 2017, 3, 1511.	3.4	131

#	Article	IF	Citations
73	Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial. Clinical Cancer Research, 2017, 23, 3510-3519.	3.2	130
74	Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. JCI Insight, 2016, 1, e87415.	2.3	125
75	Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 165-174.	1.8	123
76	Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. JAMA Oncology, 2016, 2, 518.	3.4	121
77	Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncology, The, 2022, 23, 279-291.	5.1	118
78	Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).. Journal of Clinical Oncology, 2021, 39, 9503-9503.	0.8	116
79	PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. Cancer Immunology Research, 2015, 3, 1308-1315.	1.6	114
80	Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy. Cancer Immunology Research, 2017, 5, 1133-1140.	1.6	114
81	Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell, 2018, 173, 624-633.e8.	13.5	113
82	Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions. Clinical Cancer Research, 2017, 23, 4671-4679.	3.2	110
83	Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment. European Journal of Radiology, 2015, 84, 1259-1268.	1.2	105
84	Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade. Cancer Discovery, 2021, 11, 1524-1541.	7.7	103
85	Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1â€“derived oncolytic immunotherapy. Expert Review of Anticancer Therapy, 2015, 15, 1389-1403.	1.1	102
86	Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 3398-3403.	3.3	101
87	A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney International, 2021, 100, 196-205.	2.6	95
88	Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncology, The, 2018, 19, e20-e32.	5.1	87
89	Talimogene Laherparepvec for the Treatment of Advanced Melanoma. Clinical Cancer Research, 2016, 22, 3127-3131.	3.2	80
90	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clinical Cancer Research, 2019, 25, 2174-2184.	3.2	80

#	Article	IF	Citations
91	Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?. , 2014, 2, 17.		77
92	Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. , 2015, 3, 3.		76
93	Health-related quality of life results from the phase III CheckMate 067 study. European Journal of Cancer, 2017, 82, 80-91.	1.3	76
94	Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management. Cancer, 2018, 124, 1111-1121.	2.0	72
95	Immune-checkpoint blockade â€" durable cancer control. Nature Reviews Clinical Oncology, 2016, 13, 77-78.	12.5	71
96	TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. Cancer Immunology Research, 2021, 9, 1202-1213.	1.6	71
97	Tumor Response Dynamics of Advanced Nonâ€"small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. Clinical Cancer Research, 2017, 23, 5737-5744.	3.2	69
98	Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. British Journal of Cancer, 2016, 115, 252-260.	2.9	66
99	Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). Neuro-Oncology, 2021, 23, 1961-1973.	0.6	66
100	Cytotoxic T Cells in PD-L1â€"Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. Cancer Immunology Research, 2016, 4, 1038-1048.	1.6	62
101	Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. Cancer Immunology Research, 2015, 3, 855-863.	1.6	60
102	Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. Cancer Immunology Research, 2018, 6, 1039-1045.	1.6	60
103	Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event. Cancer Immunology Research, 2018, 6, 630-635.	1.6	59
104	Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. Clinical Cancer Research, 2019, 25, 6061-6072.	3.2	58
105	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. European Journal of Cancer, 2021, 144, 182-191.	1.3	57
106	Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma. Cancer, 2015, 121, 4007-4015.	2.0	56
107	Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma. Genes and Diseases, 2018, 5, 46-48.	1.5	53
108	Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies. Cancer Immunology, Immunotherapy, 2018, 67, 1833-1844.	2.0	52

#	Article	IF	Citations
109	A phase I trial of panobinostat (<scp>LBH</scp>589) in patients with metastatic melanoma. Cancer Medicine, 2016, 5, 3041-3050.	1.3	51
110	Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. , 2014, 2, 40.		50
111	Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naÃ¯ve patient melanomas. Clinical Epigenetics, 2015, 7, 59.	1.8	49
112	Radiologic Heterogeneity in Responses to Antiâ€“PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma. Cancer Immunology Research, 2016, 4, 12-17.	1.6	49
113	Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade. Cancer Discovery, 2020, 10, 1296-1311.	7.7	49
114	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 1371-1380.	3.2	49
115	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. Cancer Immunology Research, 2020, 8, 1075-1084.	1.6	47
116	Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies. Nature Communications, 2019, 10, 5157.	5.8	46
117	ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 6919-6924.	3.3	45
118	Vitamin D deficiency is associated with a worse prognosis in metastatic melanoma. Oncotarget, 2017, 8, 6873-6882.	0.8	45
119	The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitorâ€“Related Thyroid Disorders. Cancer Immunology Research, 2019, 7, 1214-1220.	1.6	44
120	Combinatorial Cancer Immunotherapy. Advances in Immunology, 2006, 90, 341-368.	1.1	43
121	Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer. Cancer Immunology Research, 2017, 5, 1046-1055.	1.6	42
122	Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. , 2017, 5, 66.		37
123	Vitamin D intake is associated with decreased risk of immune checkpoint inhibitorâ€induced colitis. Cancer, 2020, 126, 3758-3767.	2.0	37
124	Integrated molecular drivers coordinate biological and clinical states in melanoma. Nature Genetics, 2020, 52, 1373-1383.	9.4	36
125	The biologic importance of tumorâ€infiltrating lymphocytes. Journal of Cutaneous Pathology, 2010, 37, 48-53.	0.7	35
126	Drug-Related Pneumonitis in the Era of Precision Cancer Therapy. JCO Precision Oncology, 2017, 1, 1-12.	1.5	35

#	Article	IF	Citations
127	Soluble PD-L1 as an early marker of progressive disease on nivolumab. , 2022, 10, e003527.		35
128	Biologic Activity of Autologous, Granulocyteâ€“Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. Clinical Cancer Research, 2015, 21, 3178-3186.	3.2	34
129	Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis. JCO Oncology Practice, 2020, 16, e933-e942.	1.4	33
130	Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors. Cancer Immunology, Immunotherapy, 2021, 70, 2209-2221.	2.0	32
131	Effect of corticosteroid dosing on outcomes in highâ€grade immune checkpoint inhibitor hepatitis. Hepatology, 2022, 75, 531-540.	3.6	32
132	Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study. Clinical Cancer Research, 2020, 26, 5631-5637.	3.2	31
133	Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. Blood, 2021, 137, 1353-1364.	0.6	31
134	SOX10 Regulates Melanoma Immunogenicity through an IRF4â€“IRF1 Axis. Cancer Research, 2021, 81, 6131-6141.	0.4	31
135	Outcomes after resumption of immune checkpoint inhibitor therapy after highâ€grade immuneâ€mediated hepatitis. Cancer, 2020, 126, 5088-5097.	2.0	30
136	Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naÃ¯ve or experienced for immune checkpoint blockade. , 2022, 10, e004076.		30
137	Concerted Potent Humoral Immune Responses to Autoantigens Are Associated with Tumor Destruction and Favorable Clinical Outcomes without Autoimmunity. Clinical Cancer Research, 2008, 14, 3896-3905.	3.2	28
138	Current strategies for intratumoural immunotherapy â€“ Beyond immune checkpoint inhibition. European Journal of Cancer, 2021, 157, 493-510.	1.3	28
139	Bidirectional cross talk between patientâ€derived melanoma and cancerâ€associated fibroblasts promotes invasion and proliferation. Pigment Cell and Melanoma Research, 2016, 29, 656-668.	1.5	27
140	Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. Clinical Cancer Research, 2020, 26, 5086-5091.	3.2	27
141	Metastatic mucosal melanoma: imaging patterns of metastasis and recurrence. Cancer Imaging, 2013, 13, 626-632.	1.2	26
142	Corticosteroids and immune checkpoint blockade. Aging, 2015, 7, 521-522.	1.4	26
143	Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. Melanoma Research, 2018, 28, 605-610.	0.6	24
144	Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood, 2021, 137, 3212-3217.	0.6	24

#	Article	IF	Citations
145	Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients. Npj Precision Oncology, 2021, 5, 62.	2.3	23
146	Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma. Cancer Immunology, Immunotherapy, 2012, 61, 655-665.	2.0	21
147	Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma. Cancer Immunology Research, 2015, 3, 986-991.	1.6	21
148	Antitumor Granuloma Formation by CD4⁺ T Cells in a Patient With Rapidly Progressive Melanoma Experiencing Spiking Fevers, Neuropathy, and Other Immune-Related Toxicity After Treatment With Ipilimumab. Journal of Clinical Oncology, 2015, 33, e32-e35.	0.8	21
149	Fitness Landscape of Clonal Hematopoiesis Under Selective Pressure of Immune Checkpoint Blockade. JCO Precision Oncology, 2020, 4, 1027-1033.	1.5	20
150	An Open-Label, Doseâ€“Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. Clinical Cancer Research, 2016, 22, 5204-5210.	3.2	19
151	High-Throughput Mass Cytometry Staining for Immunophenotyping Clinical Samples. STAR Protocols, 2020, 1, 100055.	0.5	19
152	Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for nonâ€“small cell lung cancer and melanoma brain metastases. Cancer, 2020, 126, 5274-5282.	2.0	19
153	<scp>PD</scp>â€1 inhibitorâ€related pneumonitis in lymphoma patients treated with singleâ€agent pembrolizumab therapy. British Journal of Haematology, 2018, 180, 752-755.	1.2	18
154	Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients. , 2016, 4, 32.		17
155	Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218). Melanoma Research, 2021, 31, 67-75.	0.6	15
156	Detection of clinically relevant immune checkpoint markers by multicolor flow cytometry. Journal of Biological Methods, 2019, 6, e114.	1.0	14
157	Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067. , 2021, 9, e003743.		14
158	Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity. Laboratory Investigation, 2017, 97, 207-216.	1.7	13
159	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. European Journal of Cancer, 2021, 157, 391-402.	1.3	13
160	Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). Clinical Cancer Research, 2021, 27, 5038-5048.	3.2	13
161	GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial. Blood Advances, 2022, 6, 2183-2194.	2.5	12
162	Development of an 8-color antibody panel for functional phenotyping of human CD8+ cytotoxic T cells from peripheral blood mononuclear cells. Cytotechnology, 2018, 70, 1-11.	0.7	11

#	Article	IF	Citations
163	Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. JCO Precision Oncology, 2022, , .	1.5	11
164	Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma. Nature Clinical Practice Oncology, 2008, 5, 696-697.	4.3	10
165	Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized Leukoplakia. Cancer Research Communications, 2021, 1, 30-40.	0.7	10
166	Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors. , 2022, 10, e003569.		10
167	The B7-H1/PD-1 pathway in cancers associated with infections and inflammation: opportunities for therapeutic intervention. Chinese Clinical Oncology, 2013, 2, 7.	0.4	9
168	Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge. Journal of Neuro-Oncology, 2016, 129, 389-393.	1.4	7
169	Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial. , 2021, 9, e003318.		7
170	Standardized 11-color flow cytometry panel for the functional phenotyping of human T regulatory cells. Journal of Biological Methods, 2020, 7, e131.	1.0	6
171	Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma. Cancers, 2022, 14, 2300.	1.7	6
172	Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade. Cancer Medicine, 2021, 10, 2627-2635.	1.3	5
173	Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service. , 2020, 8, e000992.		4
174	Long-term Overall Survival and Predictors in Antiâ€“PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study. Journal of Immunotherapy, 2021, 44, 307-318.	1.2	4
175	Targeted modified IL-2 (NHS-IL2, MSB0010445) combined with stereotactic body radiation in advanced melanoma patients after progression on ipilimumab: Assessment of safety, clinical, and biologic activity in a phase 2a study.. Journal of Clinical Oncology, 2014, 32, TPS9107-TPS9107.	0.8	4
176	A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade. Haematologica, 2021, 106, 651-654.	1.7	4
177	Immunity to the Vacuolar ATPase Complex Accessory Unit ATP6S1 in Patients with Malignant Melanoma. Cancer Immunology Research, 2015, 3, 59-67.	1.6	3
178	Immunity to X-linked inhibitor of apoptosis protein (XIAP) in malignant melanoma and check-point blockade. Cancer Immunology, Immunotherapy, 2019, 68, 1331-1340.	2.0	3
179	Multiple high-grade and rare immune-related adverse events in a colon cancer patient with genomic and cytokine profiling. Immunotherapy, 2022, 14, 843-850.	1.0	3
180	Preface. Hematology/Oncology Clinics of North America, 2014, 28, xiii-xiv.	0.9	2

#	Article	IF	Citations
181	Mass cytometry staining for human bone marrow clinical samples. STAR Protocols, 2022, 3, 101163.	0.5	1
182	Simplified mass cytometry protocol for in-plate staining, barcoding, and cryopreservation of human PBMC samples in clinical trials. STAR Protocols, 2022, 3, 101362.	0.5	1
183	Risk of Bias and Heterogeneityâ€"Reply. JAMA Oncology, 2017, 3, 858.	3.4	0
184	OR19-5 The Impact Of High Dose Glucocorticoids On The Outcome Of Immune Checkpoint Inhibitor-related Thyroid Disorders And The Baseline TSH As A Predictive Biomarker. Journal of the Endocrine Society, 2019, 3, .	0.1	0
185	Reply to T. Olivier et al. Journal of Clinical Oncology, 2022, , JCO2200209.	0.8	0